Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools

SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, England--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Eleven Therapeutics, a company leading the AI revolution in nucleic acid therapies, today announced that they have created a replicon...

Click to view original post